Terms: = Thyroid cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
6 results:
1. Implications of PD-1, Tim-3, and TIGIT Expression for cancer Immunity and Pancreatic cancer Prognosis.
Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
[TBL] [Abstract] [Full Text] [Related]
2. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
[TBL] [Abstract] [Full Text] [Related]
3. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN thyroid cancer.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract] [Full Text] [Related]
4. Endocrine side effects of cancer immunotherapy.
Cukier P; Santini FC; Scaranti M; Hoff AO
Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
[TBL] [Abstract] [Full Text] [Related]
5. [Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine].
Jurecka-Tuleja B; August R; Kukulska A; Bartnikowa W; Deja R; Czernik E; Handkiewicz-Junak D
Wiad Lek; 2001; 54 Suppl 1():378-82. PubMed ID: 12182053
[TBL] [Abstract] [Full Text] [Related]
6. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
[TBL] [Abstract] [Full Text] [Related]
